Objective: The aims of the study were to assess cognitive functions (CF) in patients with mixed connective tissue disease (MCTD) and to compare MCTD patients with systemic lupus erythematosus patients with and without neuropsychiatric manifestations (NP-SLE and non-NP-SLE, respectively) in terms of CF. Methods: Neuropsychological examination was performed in 141 patients: 30 with MCTD (24 women, 6 men), mean age: 48.07 years, 37 with non-NP-SLE (36 women, 1 man), mean age: 40.76 years and 74 with NP-SLE (68 women, 6 men), mean age: 41.97 years. Neuropsychological tests and structured interview were used. Emotional state was assessed by Hospital Anxiety and Depression Scale and clinical review. Results: We observed cognitive impairment in six MCTD patients (20%); in one (3%) the impairment was severe. MCTD patients achieved significantly higher results in seven out of 11 tests compared with patients with NP-SLE. MCTD and non-NP-SLE patients did not differ significantly. The differences were irrespective of premorbid IQ, education, disease duration and steroid treatment. Conclusions: In the majority of MCTD patients, CF were not impaired and severe impairment was unusual. Cognitive functioning was most disturbed in NP-SLE. The cognitive deficits observed in connective tissue diseases can be connected with nervous system involvement.
SharpGCIrvinWSTanEMGouldRGHolmanRH. Mixed connective tissue disease – an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med1972; 52: 148–159.
2.
BennettRMO’ConnellDJ. Mixed connective tissue disease: a clinicopathologic study of 20 cases. Semin Arthritis Rheum1980; 10: 25–51.
3.
Bellando-RandoneSCutoloMCzirjakLMatucci-CerinicM. Mixed connective tissue disease, a roundabout to rheumatic diseases?. Cur Rheum Rev2009; 5: 133–140.
SharpGC. Diagnostic criteria for classification of MCTD. In: KasukawaRSharpGC (eds) Mixed connective tissue diseases and antinuclear antibodies. Amsterdam: Elsevier; 1987. p. 23–32.
6.
Alarcon-SegoviaDVillarealM. Classification and diagnostic criteria for mixed connective tissue disease. In: KasukawaRSharpGC (eds) Mixed connective tissue diseases and antinuclear antibodies. Amsterdam: Elsevier; 1987. p. 33–40.
7.
FarheyYHessEV. Mixed connective tissue disease (MCTD) and undifferentiated connective tissue disease (UCTD). Current Rheum Rev2006; 2: 261–267.
8.
KasukawaRTojoTMiyawakiS. Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: KasukawaRSharpGC (eds) Mixed connective tissue diseases and antinuclear antibodies. Elsevier; 1987. p. 41–47.
9.
PerkinsKHoffmanRWBezruczkoNRaschA. Analysis for classification of systemic lupus erythematosus and mixed connective tissue disease. J Appl Meas2008; 9: 136–150.
10.
BurdtMAHoffmanRWDeutscherSLWangGSJohnsonJCSharpGC. Long-term outcome in mixed connective tissue disease. Longitudinal clinical and serologic findings. Arthritis Rheum1999; 42: 899–909.
11.
KurokiMOkayamaAKuwataG. A case of mixed connective tissue disease with lupus-like manifestations of the central nervous system, successfully treated with cyclophosphamide combined with prednisolone. Ryūmachi2000; 40: 627–632[Article in Japanese].
12.
SchedelJKuchenbuchSSchoelmerichJFeuerbachSGeisslerAMueller-LadnerU. Cerebral lesions in patients with connective tissue disease and systemic vasculitides: are there specific patterns?. Ann NY Acad Sci2010; 1193: 167–175.
HabetsWJDe RooijDJSaldenMH. Antibodies against distinct nuclear matrix protein are characteristic for mixed connective tissue disease. Clin Exp Immunol1983; 54: 265–276.
15.
RayesHSheikhADalaanASalehS. Mixed connective tissue disease: the King Faisal Specialist Hospital Experience. Ann Saudi Med2002; 21: 43–46.
16.
BennettRMBongDMSpargoBH. Neuropsychiatric problems in mixed connective tissue disease. Am J Med1978; 65: 955–962.
17.
SatoTFujiiTYokoyamaT. Anti-U1 RNP antibodies in cerebrospinal fluid are associated with central neuropsychiatric manifestations in systemic lupus erythematosus and mixed connective tissue disease. Arthritis Rheum2010; 62: 3730–3740.
18.
LeibfarthJHPersellinRH. Characteristics of patients with serum antibodies to extractable nuclear antigens. Arthritis Rheum1976; 19: 851–856.
19.
HojailiBBarlandP. Trigeminal neuralgia as the first manifestation of mixed connective tissue disorder. JCR: J Clin Rheumatol2006; 12: 145–147.
20.
FlechnerK-MBaumK. Mixed connective tissue disease: recurrent episodes of optic neuropathy and transverse myelopathy. Successful treatment with plasmapharesis. J Neurol Sci1994; 126: 146–148.
SiemińskiMWiśniewskaMCzuszyńskaZ. [Rozpowszechnienie zespołu niespokojnych nóg w populacji pacjentów z chorobami układowymi tkanki łącznej]. Prevalence of the restless leg syndrome in the population of the patients with systemic connective tissue diseases. Sen2005; 5: 33–38[Article in Polish].
23.
HämmenkorpiRRuuskaPForsbergSTiilikainenAMäkitaloRHakalaM. More evidence of distinctive features of mixed connective tissue disease. Scan J Rheumatol1993; 22: 63–68.
MatsuiHUdakaFOdaMKuboriTNishinakaKKameyamaM. Encephalopathy and severe neuropathy due to probable systemic vasculitis as an initial manifestation of mixed connective tissue disease. Neurology India2006; 54: 83–85.
26.
Ad Hoc Committee of Neuropsychiatric Lupus NomenclatureACR. The American College of Rheumatology nomenclature and case definition for neuropsychiatric lupus syndromes, ACR ad hoc committee on neuropsychiatric lupus nomenclature. Arthritis Rheum1999; 42: 599–608.
27.
BreyRLHollidaySLSakladAR. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology2002; 58: 1214–1220.
28.
MoscaMTaniChAringerM. EULAR recommendations for monitoring systemic lupus erythematosus patients in clinical practice and in observational studies. Ann Rheum Dis2010; 69: 1269–1274.
29.
AinialaHHietaharjuALoukkolaJ. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Care Res2001; 45: 419–423.
30.
CarbotteRMDenburgSDDenburgJA. Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis1986; 174: 357–364.
31.
CarlomagnoSMigliaresiSAmbrosoneLSanninoMSangesGDi IorioG. Cognitive impairment in systemic lupus erythematosus: a follow-up study. J Neurol2000; 247: 273–279.
32.
Nowicka-SauerKCzuszyńskaZSmoleńskaZSiebertJ. Neuropsychological assessment in systemic lupus erythematosus patients: clinical usefulness of first-choice diagnostic tests in detecting cognitive impairment and preliminary diagnosis of neuropsychiatric lupus. Clin Exp Rheumatol2011; 29: 299–306.
33.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725 (letter)–1725 (letter).
34.
NelsonHEMcKennaP. The use of current reading ability in the assessment of dementia. Br J Soc Clin Psychol1975; 14: 259–267.
35.
ZigmondASSnaithRP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand1983; 67: 361–370.
36.
LoukkolaJLaineMAinialaH. Cognitive impairment in systemic lupus erythematosus and neuropsychiatric systemic lupus erythematosus: a population-based neuropsychological study. J Clin Exp Neuropsychol2003; 25: 145–151.
37.
MonasteroRBettiniPDel ZottoE. Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations. J Neurol Sci2001; 184: 33–39.
38.
HarboeETjensvollABMaroniS. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and primary Sjögren syndrome: a comparative population-based study. Ann Rheum Dis2009; 68: 1541–1546.
39.
HayEMHuddyABlackD. A prospective study of psychiatric disorder and cognitive function in systemic lupus erythematosus. Ann Rheum Dis1994; 53: 298–303.
40.
DenburgSDStewartKEHartLEDenburgJA. How ‘soft’ are soft neurological signs? The relationship of subjective neuropsychiatric complaints to cognitive function in systemic lupus erythematosus. J Rheumatol2003; 30: 1006–1010.
41.
KozoraEEllisonMCWestS. Depression, fatigue and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Rheum2006; 55: 628–635.
42.
Banecka-MajkutewiczZDobrzyńskaLKrześniak-BohdanMKoseda-DraganM. [Wczesne objawy neurologiczne u chorych z toczniem rumieniowatym układowym]. Early symptoms of the nervous system involvement in patients with systemic lupus erythematosus (SLE). Postępy Psychiatr Neurol2001; 10: 137–143 [Article in Polish].
43.
BertsiasGIoannidisJPABoletisJ. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis2008; 67: 195–205.
